Detection and analysis of CYP2C19*2/*3/*17 allele in 318 patients with suspected invasive fungal infection to be treated with voriconazole in Guangzhou

doi:10.3760/cma.j.issn.1007-1245.2023.09.008

Abstract

Abstract:

Objective　To understand the polymorphisms of CYP2C19^*2/^*3/^*17 alleles 9154G>A, 7948G>A, and 806C>T in Guangzhou population, and to provide reference for the clinical application of voriconazole in the treatment of invasive fungal infections. Methods　A total of 318 patients with suspected invasive fungal infection who were scheduled to be treated with voriconazole and were tested for CYP2C19^*2/^*3/^*17 allele in Guangzhou Chest Hospital from January 2022 to February 2023 were selected for analysis, including 249 males and 69 females, aged 19-94 years (with a mean age of 58 years old). The polymorphism of CYP2C19^*2 (9154G>A), CYP2C19*3 (7948G>A), and CYP2C19*17 (806C>T) in the patients was detected by digital fluorescence molecular hybridization sequencing. The distribution frequencies of genotypes and haplotypes in patients with fast, medium, and slow voriconazole metabolism types were analyzed. Results　GG, AG, and AA genotypes were detected on the CYP2C19*2 (9154G>A) locus, with the distribution frequencies of 47.80% (152/318), 42.45% (135/318), and 9.75% (31/318), respectively. GG, GA, and AA genotypes were detected on the CYP2C19*3 (7948G>A) locus, with the distribution frequencies of 90.88% (289/318), 8.81% (28/318), and 0.31% (1/318), respectively. CC and CT genotypes were detected on the CYP2C19*17 (806C>T) locus, with the distribution frequencies of 99.37% (316/318) and 0.63% (2/318), respectively. In the 318 patients to be treated with voriconazole, there were 135 (42.45%), 140 (44.03%), and 43 (13.52%) patients with fast, medium, and slow voriconazole metabolism types, respectively. The haplotypes of the 3 gene loci were 2 fast metabolism haplotypes of GG-GG-GC and GG-GG-CT, with the distribution frequencies of 99.26% (134/135) and 0.74% (1/135), 3 medium metabolism haplotypes of AG-GG-CC, GG-GA-CC, and AG-GG-CT, with the distribution frequencies of 87.86% (123/140), 11.43% (16/140), and 0.71% (1/140), and 4 medium metabolism haplotypes of AA-GG-CC, AG-GA-CC, AA-GA-CC, and GG-AA-CC, with the distribution frequencies of 69.77% (30/43), 25.58% (11/43), 2.33% (1/43), and 2.33% (1/43). Conclusions　From the genetic background of CYP2C19 gene, although most people in Guangzhou are fast and medium voriconazole metabolism types, slow voriconazole metabolism type account for a certain proportion. Therefore, the attention should be paid to the detection of its gene polymorphism in clinical diagnosis and treatment, so as to guide the reasonable clinical application of voriconazole.

Key words:

Gene polymorphism, Cytochrome P450 CYP2C19 , gene, Voriconazole, Digital fluorescent molecular hybridization sequencing

摘要：

目的　了解广州地区人群CYP2C19^*2/^*3/^*17等位基因9154G>A、7948G>A和806C>T位点的多态性，为临床应用伏立康唑治疗侵袭性真菌感染提供参考依据。方法　选取2022年1月至2023年2月在广州市胸科医院就诊、拟应用伏立康唑治疗且进行CYP2C19^*2/^*3/^*17等位基因检测的318例疑似侵袭性真菌感染患者纳入分析，其中男249例、女69例，年龄19～94岁，平均58岁。应用数字荧光分子杂交测序技术检测CYP2C19^*2（9154G>A）、CYP2C19^*3（7948G>A）、CYP2C19^*17（806C>T）位点的多态性，描述性分析伏立康唑快、中、慢代谢型患者的基因型、单倍型分布频率。结果　在CYP2C19^*2（9154G>A）位点上检测到GG、AG、AA 3种基因型，分布频率分别为47.80%（152/318）、42.45%（135/318）、9.75%（31/318）；在CYP2C19^*3（7948G>A）位点上检测到GG、GA、AA 3种基因型，分布频率分别为90.88%（289/318）、8.81%（28/318）、0.31%（1/318）；在CYP2C19^*17（806C>T）位点上检测到CC、CT 2种基因型，分布频率分别为99.37%（316/318）、0.63%（2/318）。318例拟应用伏立康唑治疗的患者中，快、中、慢代谢型的患者分别有135例（42.45%）、140例（44.03%）和43例（13.52%），3个基因位点单倍型情况为：GG-GG-GC、GG-GG-CT 2种快代谢单倍型，分布频率分别为99.26%（134/135）和0.74%（1/135）；AG-GG-CC、GG-GA-CC、AG-GG-CT 3种中间代谢单倍型，分布频率分别为87.86%（123/140）、11.43%（16/140）和0.71%（1/140）；AA-GG-CC、AG-GA-CC、AA-GA-CC、GG-AA-CC 4种中间代谢单倍型，分布频率分别为69.77%（30/43）、25.58%（11/43）、2.33%（1/43）和2.33%（1/43）。结论　从CYP2C19基因遗传背景看，广州地区人群虽多为伏立康唑快、中代谢型，但慢代谢型占有一定比例，在临床诊疗中应重视其基因多态性检测，进而指导伏立康唑的临床合理应用。

关键词:

基因多态性, 细胞色素P450 , CYP2C19基因, 伏立康唑, 数字荧光分子杂交测序技术

Yang Jianliang, Su Duohua, Li Xiang, Zhou Xiaowen, Zhi Jialing, Xing Zhenjian, Zhong Honglan.

Detection and analysis of CYP2C19^*2/^*3/^*17 allele in 318 patients with suspected invasive fungal infection to be treated with voriconazole in Guangzhou [J]. International Medicine and Health Guidance News, 2023, 29(9): 1214-1217.

杨建良苏铎华李祥周晓雯植嘉玲邢贞建钟洪兰.

广州地区318例拟应用伏立康唑治疗的疑似侵袭性真菌感染患者CYP2C19^*2/^*3/^*17等位基因检测分析 [J]. 国际医药卫生导报, 2023, 29(9): 1214-1217.

References

[1] Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics[J]. Lancet, 2019, 394(10197): 521-532. DOI: 10.1016/S0140-6736(19)31276-0.
[2] Pirmohamed M. Pharmacogenomics: current status and future perspectives[J]. Nat Rev Genet, 2023: 27. DOI: 10.1038/s41576-022-00572-8.
[3] Katzung BG. 基础与临床药理学[M]. 金有豫,唐玉,张殿增, 译. 13版. 北京: 人民卫生出版社, 2020: 61-72.
[4] Jemel S,Guillot J,Kallel K,et al.In vivo efficacy of voriconazole in a galleria mellonella model of invasive infection due to azole-susceptible or resistant aspergillus fumigatus isolates[J].J Fungi (Basel), 2021, 7(12): 1012. DOI: 10.3390/jof7121012.
[5] Zhang Y, Hou K, Liu F, et al. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: systematic review and meta-analysis[J]. Mycoses,2021,64(8):860-873. DOI: 10.1111/myc.13293.
[6] Blanco-Dorado S,Maroñas O,Latorre-Pellicer A,et al.Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a spain pharmacogenetic- pharmacokinetic prospective multicenter study[J].Pharmacotherapy,2020,40(1):17-25. DOI: 10.1002/phar.2351.
[7] 林明瑞,余新华,刘华荣. CYP2C19基因多态性对伏立康唑疗效的影响[J]. 福建医药杂志,2023,45(1):27-30. DOI:10.3969/j.issn.1002-2600.2023.01.010.
[8] Li S,Wu S,Gong W,et al.Application of population pharmacokinetic analysis to characterize CYP2C19 mediated metabolic mechanism of voriconazole and support dose optimization[J].Front Pharmacol,2022,12:730826. DOI: 10.3389/fphar.2021.730826.
[9] 丁健.高等药理学[M]. 2版. 北京:科学技术出版社,2019:659-676.
[10] Ahmed S,Gul S,Akhlaq M,et al. Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan[J].Bioengineered, 2021,12(1):4442-4451. DOI: 10.1080/21655979.2021.1955809.
[11] Jin C,Li Z,Zheng X,et al. Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele[J].J Clin Lab Anal,2020,34(1):e23005. DOI: 10.1002/jcla.23005.
[12] Yan Y,Hao R,Zhao X,et al. Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic stroke patients treated with clopidogrel in China: a meta-analysis[J].J Stroke Cerebrovasc Dis, 2022, 31(11): 106798. DOI: 10.1016/j.jstrokecerebrovasdis. 2022.106798.
[13] Milosavljevic F,Bukvic N,Pavlovic Z,et al.Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis[J].JAMA Psychiatry,2021,78(3):270-280. DOI: 10.1001/jamapsychiatry.2020. 3643.
[14] 牛丙寅,王冠,陈世才,等. CYP2C19基因多态性检测指导下的伏立康唑治疗侵袭性真菌感染患者效果的评价[J]. 首都医科大学学报,2018,39(3):423-427. DOI:10.3969/j.issn.1006-7795.2018.03.020.
[15] 杜红丽,王靖方,崔建勋,等. CYP2C19基因与药物代谢相关性研究进展[J]. 广东药学院学报,2008,24(5):532-535.
[16] Ahmed S,Gul S,Siraj S,et al.Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients[J].Sci Rep,2022,12(1):6171. DOI: 10.1038/s41598-022-09679-8.
[17] Carvalho Henriques B,Beatriz BA,Hu X,et al.Methodology for clinical genotyping of CYP2D6 and CYP2C19[J].Transl Psychiatry,2021,11(1):596. DOI: 10.1038/s41398-021- 01717-9.
[18] Tilleman L,Rubben K,Van Criekinge W,et al.Haplotyping pharmacogenes using TLA combined with Illumina or Nanopore sequencing[J].Sci Rep,2022,12(1):17734. DOI: 10.1038/s41598-022-22499-0.